Skip to main content

Advertisement

Table 1 Demographic features of patients on each observation year

From: Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital

 Registration1st year2nd year3rd year4th year
Patients (n)11271127997808588
Age (years)     
 Mean ± SD68.2 ± 10.269.2 ± 11.170.0 ± 10.270.7 ± 9.871.0 ± 9.4
 Median, IQR69, 62–7670, 63–7771, 64–7771, 65–7871, 65–78
Sex, female (%)799 (70.9)799 (70.9)714 (71.6)595 (73.6)441 (75.0)
Disease duration (months)     
 Mean ± SD123.4 ± 115.1135.5 ± 115.5147.7 ± 114.5163.6 ± 114.1177.3 ± 112.0
 Median, IQR93, 36–169105, 48–181117, 61–193112, 80–207147, 97–218
DAS28 score (average, SD)3.18 ± 1.762.88 ± 1.582.92 ± 1.572.84 ± 1.522.83 ± 1.53
Change of prescription 456 (40.5)360 (36.1)282 (34.9)191 (32.5)
Prednisolone
 Number of patients (%)476 (42.2)435 (38.6)352 (35.3)280 (34.7)166 (28.2)
 Average dose (mg/day)     
  Mean ± SD4.22 ± 2.544.25 ± 2.944.21 ± 2.774.13 ± 2.923.99 ± 2.83
  ≥ 5 mg, number (%)243 (21.6)204(18.1)165 (16.5)118 (14.6)68 (11.5)
Biologic DMARDs
 Number of patients (%)302 (26.7)314(27.8)282 (28.2)244 (30.2)199 (33.8)
 Etanercept, number (%)115 (10.2)119 (10.6)105 (10.5)88 (10.9)77 (13.1)
 Infliximab, number (%)34 (3.0)30 (2.7)24 (2.4)22 (2.7)12 (2.0)
 Adalimumab, number (%)35 (3.1)28 (2.5)25 (2.5)18 (2.2)14 (2.4)
 Tocilizumab, number (%)53 (4.7)61 (5.4)59 (5.9)58 (7.2)51 (8.7)
 Abatacept, number (%)28 (2.5)34 (3.0)40 (4.0)34 (4.2)31 (5.3)
 Golimumab, number (%)33 (2.9)39 (3.5)32 (3.2)26 (3.2)13 (2.2)
 Others, number (%)4 (0.4)3 (0.3)13 (1.3)13 (1.6)9 (1.5)
Methotrexate
 Number of patients (%)886 (78.6)835 (74.1)731 (73.3)581 (71.9)414 (70.4)
 Average dose (mg/week), mean ± SD7.51 ± 3.837.49 ± 4.017.31 ± 3.967.20 ± 3.927.00 ± 3.84
Other immunosuppressive drugs
 Number of patients (%)182 (16.1)191 (16.9)168 (16.8)140 (17.3)117 (19.8)
 Tacrolimus, number (%)139 (12.3)160 (14.2)137 (13.7)114 (14.1)96 (16.3)
 Mizoribine, number (%)32 (2.8)32 (2.8)29 (2.9)24 (3.0)19 (3.2)
 Leflunomide, number (%)6 (0.5)6 (0.5)7 (0.7)6 (0.7)6 (1.0)
 Others, number (%)5 (0.5)3 (0.3)2 (0.2)3 (0.4)3 (0.5)
  1. Abbreviations: SD standard deviation, IQR interquartile range, DAS28 Disease Activity Score 28